Bank of New York Mellon’s Trinity Biotech TRIB Stock Holding History

Bank of New York Mellon’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-391	Closed	-$670K	–	4381
2015 Q3	$670K	Hold	391	–	–	﹤0.01%	3427
2015 Q2	$1.06M	Hold	391	–	–	﹤0.01%	3302
2015 Q1	$1.13M	Buy	391 +53	+16%	+$147K	﹤0.01%	3236
2014 Q4	$889K	Buy	338 +71	+27%	+$184K	﹤0.01%	3366
2014 Q3	$732K	Buy	267 +46	+21%	+$149K	﹤0.01%	3473
2014 Q2	$763K	Buy	221 +49	+28%	+$174K	﹤0.01%	3454
2014 Q1	$624K	Buy	+172	New	+$676K	﹤0.01%	3502

Other funds holding TRIB

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

AAM

ACK Asset Management Greenwich, Connecticut $801M AUM 60.42% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

LAM

Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

Bank of New York Mellon's TRIB Position: Q4 2015 in Review

Bank of New York Mellon sold out of Trinity Biotech (TRIB) in Q4 2015, closing a stake of 391 shares — an estimated $670K sold.

Bank of New York Mellon first reported a position in TRIB in Q1 2014 and held it in 7 quarters. The position peaked at $1.13M in Q1 2015. 81 funds tracked by Wall St. Rank hold TRIB as of Q4 2015.

Bank of New York Mellon reported no remaining Trinity Biotech position as of Q4 2015 after selling out during the quarter.
Bank of New York Mellon sold 391 Trinity Biotech shares in Q4 2015, an estimated $670K.
Bank of New York Mellon first reported a position in Trinity Biotech in Q1 2014 and held it in 7 quarters.
Bank of New York Mellon's Trinity Biotech position peaked at $1.13M in Q1 2015.
81 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2015.

Based on Bank of New York Mellon's 13F filing for Q4 2015, filed 12 Feb 2016.